Researcher Spotlight: Yulai Zhou, MD, PhD Yale University Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of cancer, associated with poor treatment responses and spread throughout the body. However, the mechanisms that drive these processes are poorly understood, which…
Researcher Spotlight: Herman Van Besien, MD NYU School of MedicineOliver W. Press, MD, PhD Memorial Fellow Lymphomas associated with Epstein-Barr virus (EBV) are an aggressive subset of cancer that often lack effective treatment options. “Many EBV-related lymphomas do not express…
Researcher Spotlight: Shelby Sloan, PhD The Ohio State University Classical Hodgkin’s lymphoma (cHL) is one of themost common lymphomas in adolescents and young adults. Many patients are cured with current frontline chemotherapy, but there remains a small subset who relapse…
Researcher Spotlight: Xin Meng, PhD Yale University Dr. Meng’s interest in lymphoma research began early in her academic career, when a little girl in her hometown developed lymphoma. “Her mother, desperate for help, came to me — since I was…
Researcher Spotlight: Thomas Corner, DPhil. Yale University The protein EZH2 has been found to be involved in lymphoma development and progression, and medications that inhibit its activity are important options in the treatment of lymphoma. Dr. Corner’s research is focused…
Researcher Spotlight: Federico Mario Aletti, MD The University of Texas MD Anderson Cancer Center Lymphoma treatment options have improved dramatically in recent years, leading to deep and durable remissions for many patients. However, during his time as a resident at…
Researcher Spotlight: Seda Tolu, MD The Trustees of Columbia University in the City of New York Dr. Tolu earned her medical degree from the University of Maryland School of Medicine and completed a residency in hematology and oncology at Herbert…
Researcher Spotlight: Sandeep Raj, MD Memorial Sloan Kettering Cancer Center Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of large B-cell lymphoma (LBCL), but many patients still experience cancer recurrence after their use. “Roughly half of patients will…
Researcher Spotlight: Christina Poh, MD City of Hope Nodal T follicular helper (TFH) cell lymphoma is an aggressive type of blood cancer that often responds poorly to frontline therapies such as chemotherapy and bone marrow transplant. Dr. Poh’s research aims…
Researcher Spotlight: Andrew Jallouk, MD, PhD Vanderbilt University Medical Center Chimeric antigen receptor (CAR) T-cell therapy is a lifesaving treatment option for many patients with relapsed or refractory lymphoma. Current CAR T-cell therapies are engineered from a patient’s own cells,…
